Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database

Abstract

This retrospective cohort-based study assessed the change in glycated haemoglobin A_1C (HbA_1C) in patients with type 2 diabetes, with existing prescriptions for oral antidiabetic drugs (OADs), prescribed insulin versus those prescribed subsequent OADs. A cohort of patient records drawn from the The Health Improvement Network (THIN) database was stratified by maximum concurrent number of OADs. Of 128,568 unique patient records identified, 67.7% (n=87,057) had received at least one OAD, 17.4% (n=15,138) of these patients progressed to insulin therapy. Mean HbA_1C at insulin initiation was 9.5% (one OAD), 9.6% (two), 9.7% (three) and 10.1% (four), with an average HbA_1C increase of 0.7% prior to insulin initiation. The greatest improvement in HbA_1C was achieved with insulin therapy. A threshold HbA_1C value of 8.5% above which OAD escalation is unlikely to achieve a target HbA_1C ≤ 7.0% is seen. In patients not achieving HbA_1C targets with OADs only, insulin-based regimens should be considered in preference to adding more or multiple OADs. Br J Diabetes Vasc Dis 2010;10:178—182.

Keywords

glycaemic control HbA1C insulin initiation oral hypoglycaemic agents type 2 diabetes mellitus

Get full access to this article

View all access options for this article.

References

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111.

The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long term complications in insulin dependent diabetes. N Engl J Med 1993;329:978-86.

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.

Nathan DM , Buse JB , Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32: 193-203.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.

Duckworth W. , Abraira C. , Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-39.

Department of Health. Quality and Outcomes Framework (QOF), 2009. http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/QOF/index.htm (Accessed 11 November 2009)

10.

Turner RC , Cull CA , Holman RR Glycemic control with diet, sulfonylurea, metformin and insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies. UKPDS 49. JAMA 1999;281:2005-12.

11.

Brown, JA , Nichols GA , Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40.

12.

Rubino A. , McQuay LJ , Gough SC et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412-18.

13.

Krentz AJ , Bailey CJ Oral antidiabetic agents: current role in type 2 diabetes mellitus . Drugs 2005;65:385-411.

14.

Poole CD , Tetlow T. , McEwan P. et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin 2007;23(suppl 1):S41-8.

15.

Currie CJ , Poole CD , Tetlow T. et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin 2007;23(suppl 1):S33-9. <AQ3>

16.

Pinheiro J. , Bates DM Mixed Effects Models in S and S-PLUS. New York: Springer Verlag, 2000 .

17.

National Institute of Health and Clinial Excelence. Diabetes, Type 2 diabetes: blood glucose. London: NICE, 2002. http://www.nice.org.uk/Guidance/G (Accessed 3 September 2009)

18.

National Institute of Health and Clinial Excelence. Diabetes, Type 2 (update). London: NICE, 2008. http://www.nice.org.uk/Guidance/CG66 (Accessed: 3 September 2009)

19.

BMA. QOF Changes and new indicators for 2009/10. London: BMA, 2008. http://www.bma.org.uk/employmentandcontracts/independent_contractors/quality_outcomes_framework/QoFchangesOct08.jsp (Accessed 3 September 2009)

20.

Peyrot M. , Rubin RR , Lauritzen T. et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005;28:2673-9.

21.

Surwit RS , van Tilburg MAL , Parekh PI et al. Treatment regimen determines the relationship between depression and glycemic control. Diabetes Res Clin Practice 2005;69:78-80.

22.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.